Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Class A ordinary shares, par value US$0.0001 per share
-
Shares outstanding
-
445M
-
Number of holders
-
325
-
Total 13F shares, excl. options
-
298M
-
Shares change
-
+1.19M
-
Total reported value, excl. options
-
$10.7B
-
Value change
-
+$36.5M
-
Put/Call ratio
-
0.13
-
Number of buys
-
180
-
Number of sells
-
-133
-
Price
-
$36.03
Significant Holders of Royalty Pharma plc - Class A ordinary shares, par value US$0.0001 per share (RPRX) as of Q1 2023
376 filings reported holding RPRX - Royalty Pharma plc - Class A ordinary shares, par value US$0.0001 per share as of Q1 2023.
Royalty Pharma plc - Class A ordinary shares, par value US$0.0001 per share (RPRX) has 325 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 298M shares
of 445M outstanding shares and own 66.97% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (47.4M shares), FMR LLC (40M shares), VANGUARD GROUP INC (37.9M shares), BlackRock Inc. (19.8M shares), BAILLIE GIFFORD & CO (18.9M shares), VIKING GLOBAL INVESTORS LP (11.2M shares), JPMORGAN CHASE & CO (8.67M shares), STATE STREET CORP (8.34M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (7.24M shares), and GEODE CAPITAL MANAGEMENT, LLC (5.99M shares).
This table shows the top 325 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.